Analyst Reco. Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
61.32 ^USD	-1.94%		-6.48%	-26.55%

04-26	Cytokinetics Appoints Sung Lee as CFO	MT
04-26	Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	04-09	MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating	03-06	MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61	01-24	MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating	01-19	MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market	01-08	MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept	12-27	MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating	12-27	MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating	12-27	MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating	12-27	MT
Goldman Sachs Starts Coverage on Cytokinetics with Buy Rating, $50 Price Target	11-09	MT
B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated	11-07	MT
UBS Trims Cytokinetics' Price Target to $61 From $62, Keeps Buy Rating	11-03	MT
HC Wainwright Adjusts Cytokinetics Price Target to $58 From $49, Maintains Buy Rating	23-10-20	MT
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $65 From $59, Keeps Overweight Rating	23-10-09	MT
SVB Initiates Cytokinetics at Outperform	23-08-15	MT
JPMorgan Raises Cytokinetics' Price Target to $54 From $52, Maintains Overweight Rating	23-06-22	MT
UBS Adjusts Cytokinetics Price Target to $62 From $61, Maintains Buy Rating	23-05-05	MT
UBS Adjusts Cytokinetics Price Target to $61 From $67, Maintains Buy Rating	23-04-03	MT
Cantor Fitzgerald Adjusts Price Target on Cytokinetics to $59 From $61, Maintains Overweight Rating	23-04-03	MT
JPMorgan Chase Adjusts Price Target on Cytokinetics to $52 From $55, Maintains Overweight Rating	23-03-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Analyst Reco.

Filters